PE-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein Cost No. MHC-HE005TB

MHC-HE005TP Cat. No.

| Description | |
|-------------------------|--|
| Source | Recombinant PE-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. PE-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer is assembled by biotinylated monomer and PE-labeled streptavidin. |
| | It contains Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide. |
| Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK |
| Wavelength | Excitation Wavelength: 488 nm / 561 nm |
| | Emission Wavelength: 575 nm |
| Endotoxin | Less than 1EU per μg by the LAL method. |
| Formulation and Storage | |
| Formulation | Supplied as 0.22 µm filtered solution in 20mM Tris, 200mM NaCl, 0.2% BSA (pH 8.0). |
| Storage | Valid for 6 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Background | |

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.